LDL-C, low-density lipoprotein cholesterol; LLT, lipid-lowering therapy; LPL, lipoprotein lipase; MACE, major adverse cardiovascular events; MI, myocardial infarction; MDCT, multidetector computed tomography; NEJM, New England Journal of Medicine; non-HDL-C, non–high-density lipoprotein cholesterol; PCI, percutaneous coronary intervention; PPAR-α, peroxisome proliferator-activated receptor alpha; PUFA, polyunsaturated fatty acid; q3 months, every 3 months; q4w, every 4 weeks; RRR, relative risk reduction; SC, subcutaneous; sHTG, severe hypertriglyceridemia. This evidence concerns the gene LPL and hypertriglyceridemia.